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SUMMARY: Soy isoflavones, lactobacilli, vitamin D3 and calcium. 
Observational study in menopause.
A.P. CAPUTI, V. ARCORACI, C. BENVENUTI, ESTRONET STUDY GROUP
An observational study in clinical practice was carried out to draw 
an updated profile on the actual trend in menopause management and 
to detect the clinical activity of a new phytoestrogen. Each gynaecologist 
observed up to 10 consecutive menopause women, and collected the 
data concerning history, life style, past and actual treatments, HRT 
refusal/withdrawal, current therapy, symptoms, visits/exams in the pre-
vious 3 months, through the website www.estronet.net, by a confiden-
tial and protected individual access.
The 181 gynaecologists collected a sample of 1398 menopause wo-
men of which 607 not treated, 327 on estrogens, and 464 on phytoe-
strogens. The most used phytoestrogen in the study (87.1%) contains ge-
nistin and daidzin (30+30 mg) + lactobacilli, Ca and vit. D3 (Estro-
mineral, EM) and was administered to 392 women (aged 54.1 years, 
BMI 24.8) for 112.9 days (mean) up to 1 year. Menopause symptoms 
improved on EM independently from their baseline severity and the 
improvement increased with treatment duration: flushing improved up 
to 96.2% at 1 year; nocturnal sweating 100%, palpitations 63.6%, 
and vaginal dryness 56%.
Tumour fear, absence of symptoms and fear of weight gain were the 
most frequent reasons for refusal/withdrawal of HRT. Women treated 
(HRT or phytoestrogens) were more controlled both before and during 
the treatment. In presence of concomitant clinical conditions, EM was 
preferred. Phytoestrogens plus lactobacilli and mineral supplement 
showed a satisfactory clinical activity and safety.
RIASSUNTO: Isoflavoni di soia, lattobacilli, vitamina D3 e calcio. 
Studio osservazionale in menopausa.
A.P. CAPUTI, V. ARCORACI, C. BENVENUTI, ESTRONET STUDY GROUP
Nel presente studio clinico osservazionale si sono valutati, nella 
pratica clinica quotidiana l’orientamento del ginecologo nella gestio-
ne della menopausa e l’attività clinica di uno specifico fitoestrogeno. 
Anamnesi, stile di vita, interruzione o rifiuto della terapia ormonale 
sostitutiva, trattamenti, patologie e terapie concomitanti, sintomatolo-
gia, visite e accertamenti nell’arco dell’ultimo trimestre, sono stati rac-
colti da 181 ginecologi italiani mediante il sito internet www.estronet.
net con accesso individuale riservato e protetto.
Sono state analizzate 1398 donne in menopausa di cui 607 non 
trattate, 327 trattate con estrogeni e 464 con fitoestrogeni. Il fitoestroge-
no più utilizzato nello studio (87.1%) conteneva genistina e daidzina 
(30+30 mg) + lattobacilli, Ca e vit. D3 (Estromineral - EM) ed è stato 
somministrato a 392 donne (età 54.1 anni, BMI 24.8) per 112.9 
giorni (in media) fino a 1 anno. I sintomi menopausali dopo tratta-
mento con EM sono migliorati indipendentemente dalla loro gravità 
iniziale e il miglioramento era correlato alla durata del trattamento: 
a 1 anno le vampate sono migliorate fino al 96.2%, la sudorazione 
notturna al 100%, le palpitazioni al 63.6%, e la secchezza vaginale 
al 56%. Paura di neoplasie, assenza di sintomi e paura di aumentare 
di peso sono i motivi più frequenti di rifiuto della HRT. Le donne 
trattate (con HRT o fitoestrogeni) sono sottoposte a maggiori controlli 
clinici, prima e durante il trattamento. Con patologie concomitanti, il 
fitoestrogeno più scelto è stato EM, che ha mostrato una soddisfacente 
attività clinica e sicurezza.
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Introduction
Recent scientific acquisitions and regional diffe-
rences in pharmacological approach have remodelled 
the prescription attitude in menopause (1, 2). 
Absolute and relative contraindications of hormo-
ne replacement therapy (HRT) are well known, being 
the risks of HRT represented by venous thrombo-
embolism, gallbladder stones, mammary tumour and 
endometrial cancer.
On the other hand, it’s also true that there is no 
standard therapy suitable for all menopaused women, 
as HRT is just a definition referred to different sche-
mes appropriate for specific age and clinical condi-
tion (3). In fact, HRT is a valid and safe treatment 
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for moderate/severe acute vasomotor symptoms and 
vulvo-vaginal atrophy, provided its prescription is 
personalized HRT as doses, types, routes of admini-
stration, and combination, to optimize the benefits 
and reduce the risks.
Moreover, postmenopausal estrogen use is asso-
ciated with osteoporosis prevention and, possibly, 
with a lower cardiovascular disease risk. Notwith-
standing these sure benefits, long term compliance 
with estrogens is poor mainly due to patient concer-
ns over cancer risk (4). 
Furthermore, postmenopausal women who use 
estrogen combined with progestins (to prevent endo-
metrial cancer) experience side effects such as vaginal 
bleeding (5). 
These considerations pushed doctors and women 
to find alternatives whose definite effectiveness is still 
under investigation.
The start to a new menopause approach rose from 
the observation that osteoporosis, arteriosclerosis, 
breast and uterus tumours are less frequent in some 
oriental populations. Chinese and Japanese women 
more rarely complain menopause disturbs, as flu-
shing, vaginal dryness and tissue atrophy of genital 
apparatus. These epidemiological data were attribu-
ted to alimentary habits of these populations, parti-
cularly to the great use of soy, whose seeds contain 
isoflavones, non steroidal substances with structure 
and action similar to estrogens. Isoflavones found in 
high concentrations in soy seeds are genistin and dai-
dzin that belong to phytoestrogens family and show 
selective binding to estrogen receptor sites with weak 
estrogenic effects due to the mixed estrogen ago-
nist and antagonist properties (6-8). They stimulate 
the production of Sex Hormone Binding Globulin 
and show a small but significant increase in plasma 
SHBG. This can explain their estrogenic antagonistic 
effect (9, 10), which confers them a role of natural 
selective estrogen receptor modulators with the po-
tential of beneficial effects of ERT avoiding the most 
undesired estrogenic effects (11, 12).
In postmenopausal women consuming a phytoe-
strogen-rich diet, hot flushes and vaginal dryness 
were reduced and bone mineral density was increa-
sed (13). Phytoestrogens play a role in preventing 
cardiovascular disease and certain types of hormo-
nally responsive cancers, as suggested by the data 
in Asian populations with high soy consumers (9, 
10, 14, 15).
As endogenous estrogens have a central role in the 
aetiology of endometrial cancer (16), factors that 
alter endogenous oestrogen concentrations/expres-
sion, such as phytoestrogens and their agonist/an-
tagonist action may positively influence the risk of 
the disease. On the other hand, in postmenopausal 
women, endogenous estrogen levels are very low, and 
phytoestrogens are more likely to bind to oestrogen 
receptors leading to biological effects (6, 17).
In fact Asian women show a lower incidence of 
endometrial cancer, in relation with the intake of soy 
food higher than the Western women (18). Asian 
populations consume 20–50 g of soy daily, which is 
their major source of phytoestrogens, comparable to 
a daily intake of 20–80 mg phytoestrogens (10). A 
confirmation of these data is given in a recent US 
survey, where isoflavones consumption was inversely 
related to the risk of endometrial cancer, even stron-
ger in postmenopausal women (OR= 0.44, 95%CI= 
0.26 to 0.77) (19). High intake of phytoestrogens in 
foods is uncommon in most Western countries.
A clinical pharmacology study demonstrated how 
the combination of isoflavones and estrogens redu-
ces the estradiol-induced endometrial hyperplasia in 
menopause (20). 
There are indications from observational studies 
that phytoestrogens protect against breast cancer 
(21-23). The Author’s conclusions of a recent publi-
cation on phytoestrogens and breast cancer chemo-
prevention say that despite the present ambiguity, 
current data do suggest a potential benefit from use 
of phytoestrogens in breast cancer chemoprevention 
and therapy (24). 
A project to draw an updated profile on the ac-
tual trend of Italian Gynaecologists in menopause 
NT HERT EM
Age (years) 55.5 ± 5.9 53.3 ± 5.0 54.1 ± 5.0
BMI (kg/m2) 24.6 ± 3.7 24.1 ± 3.2 24.8 ± 3.7
Systolic blood pressure (mmHg) 127.8 ± 13.6 126.5 ± 13.3 127.7 ± 13.9
Diastolic blood pressure (mmHg) 78.8 ± 8.3 77.9 ± 8.5 78.3 ± 9.4
Heart rate (beat/min) 76.7 ± 30.3 76.2 ± 7.7 75.0 ± 10.8
TABLE I - VITAL CHARACTERISTICS OF THE WOMEN STUDIED: NT NOT-TREATED, HERT ESTROGEN 
THERAPHY, EM PHYTOESTROGENS (MEANS ± SD). 
214
A.P. Caputi e Coll.
management was designed. Moreover this study was 
taken as an opportunity to verify the acceptance and 
the clinical activity of a new phytoestrogen recently 
introduced in clinical practice, in which isoflavones 
are combined to lactobacillus sporogenes, vitamin D3 
and calcium. Lattobacilli were added to the formula-
tion to supply glycosidase to the intestinal flora and 
so to guarantee the conversion of isoflavones in active 
aglyconic forms (genistein and daidzein, and the con-
version of daidzin in the more active equol) (25).
Methods
On an Internet based computerised procedure 
each gynaecologist observed up to 10 consecutive 
menopause women, whose data were recorded by 
an electronic case report form. Confidential access, 
protected by individual login and password allowed 
data input into the website www.estronet.net and 
data consultation by 181 gynaecologists.

















Fig. 1 - Education in the population studied. 
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HRT refusal/withdrawal, current pharmacological 
therapy, symptoms evaluation, visits/exams in the 3 
months preceding the visit, were collected. 
The characteristics of the not treated (NT), 
on hormone replacement therapy (HRT) and on 
phytoestrogens women were compared. Among the 
different phytoestrogens, the one combining geni-
stin and daidzin (30+30 mg) + lactobacilli, Ca and 
vit D3 [Estromineral, Rottapharm (EM)] was largely 
the most used in the study (87.1%), representing a 
novelty for its composition.
A statistical description of the groups and their 
comparison by means of χ2 square test were carried 
out when appropriate. 
Results
The study was carried out between May 2003 
























Fig. 4 - HRT refusal/withdrawal reasons in not-treated women.
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neous 86.6% surgical 13.4%), of which 327 women 
(23.6%) were treated with Hormone (or Oestrogen) 
Replacement Therapy (HERT), 464 (33.5%) were on 
phytoestrogens and 607 (43.9%) received no specific 
treatment for menopause (NT). The estrogens used 
in HRT were represented by transdermal 64%, oral 
18%, gel 12% and spray 6%; in 1.1% of the women 
they were administered in combination with phytoe-
strogens. 
EM was administered to 392 women for a mean 
duration of 112.9 days. 
The vital characteristics (mean ± SD) of the popu-
lation were similar in the groups compared for age; 
blood pressure and heart rate (Tab. I).
The allocation to type of treatment showed no dif-
ferences for Primary school Education, prevalence for 
NT for Secondary school, and for HERT and EM, 
respectively, in High school and University educated 
women (Fig. 1). Among professions, the employee 
group chose/received more frequently an active treat-
ment, while retired women preferred the non treat-
ment (Fig. 2). No differences among groups for the 
civil status (Fig. 2).
Diet was more adopted by women on EM (30.4) 
and HERT (28.7%) than by NT (22.2%); while no 
clear differences rose for the others items of lifestyle 
considered (Fig. 3).
The more frequent reasons for HRT refusal or 
withdrawal were the tumour fear, the absence of me-
nopause symptoms and a big area of non advised or 
non informed (Fig. 4).
Women treated (HERT or EM) underwent more 
exams both before and during the treatment than NT 
women (Fig. 5).
The most frequent concomitant pathological con-
ditions were arthrosis, benign mammary diseases and 
hypertension, followed by osteoporosis (Fig. 6). The 


































Fig. 5 - Exams carried out within the three months before the visit.
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HERT. When breast cancer was present, the treat-
ment choice felt almost exclusively on EM or NT. 
The most frequently concomitant therapies repor-
ted were calcium+vitamin D3 and antihypertensive 
drugs (Fig. 7).
At start, the most present symptoms on EM treat-
ment were flushing and nocturnal sweating (Fig. 8). 
The rate of EM responders was independent from the 
severity of menopause symptoms at start of EM treat-
ment (Fig. 9). The clinical response to EM increased 
in relation with treatment duration (Fig. 10) and was 
superior to the alternative phytoestrogen group, as 
flushing (p< 0.04) and nocturnal sweating (p= 0.07) 
were concerned (Fig. 11).
Discussion
Women with a very low education (primary) 
trusted more in the gynaecologist advice and no 
difference among allocation to treatments was 
detected, a poor education (secondary) addressed 






























































Fig. 7 - Concomitant therapies according to the stratification in menopause treatments.
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to a non treatment choice, and high education 
pushed to oestrogen treatment, while university 
formation favoured the decision to alternative 
therapies in response to doubts of safety.
Women who accept whatever a treatment, de-
clared to be much more on diet than the non-
treated, showing a higher interest for their fitness. 
In the mean time it can be observed that women 
compliant to HRT or phytoestrogens treatment 
are much more controlled than the not-treated.
Examining the different reasons to refuse or 
abandon HRT, it clearly appears that beside the 
fear of tumour, a very large sample of the popu-
lation (globally more than 23%) manifested inac-
curate information (never proposed/not informed, 
unadvised by family doctor, or not even able to spe-
cify the reason). This outcome identifies the need 
for improving the communication towards the me-
nopause women  to increase their awareness of the 
risk and benefit of a correct approach.
In presence of concomitant pathological condi-
tions, the rate of EM users was higher than HRT 
users and similar to NT incidence. When breast 
cancer was involved, the treatment choice felt al-
most exclusively on EM or NT. 
Data on concomitant therapies show the com-











































Fig. 9 - Clinical activity of EM according to the symptoms severity at EM start.
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Conclusions
This observational study confirmed the reasons 
for refusal/withdrawal of HRT. 
Women treated (HRT or phytoestrogens) ap-
pear more controlled both before and during the 
treatment.
An opportunity to verify the clinical activity of a 
new phytoestrogen, in which isoflavones are com-
bined to lactobacilli, vitamin D3 and calcium, in 
clinical practice.
In presence of concomitant clinical condi-
tions, the natural approach with phytoestrogens 
is preferred. 
Phytoestrogens plus lactobacilli and mineral sup-
plement show a satisfactory clinical activity, correla-






































Fig. 11 - Comparative clinical activity between EM and other phytoestrogens.
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